|
VALISH
Valsartan in elderly Isolated Systolic Hypertension
Ongoing trial
 |
Author(s) |
Ogihara T, Saruta T, Matsuoka H, Shimamoto K, Fujita T, Shimada K, Imai Y, Nishigaki M |
 |
Title(s) |
Valsartan in Elderly Isolated Systolic Hypertension (VALISH) study: rationale and design |
|
Reference(s) |
Hypertens Res 2004;27:657–61 |
|
Disease |
Hypertension |
|
Purpose |
To compare the incidence of cardiovascular events between two target SBP levels (< 140 mm Hg and < 150 mm Hg) under treatment with valsartan as initial therapy in elderly patients with isolated systolic hypertension |
|
Study design |
Randomised, open, parallel-group |
|
Follow-up |
Aim at least 2 years |
|
Patients |
Aim 3000 patients, aged > 70 and < 85 years, with SBP ≥ 160 mm Hg and DBP < 90 mm Hg that is untreated or being treated with another therapy that can be switched to valsartan
|
|
Treatment regimen |
Valsartan, 40–80 mg/day, to target SBP < 140 mm Hg or < 150 mm Hg, increased up to 160 mg/day if target BP not achieved within 1–2 months |
|
Concomitant therapy |
Other antihypertensive agents, except other angiotensin-receptor blockers, may be added if valsartan alone is inadequate |
|
Results |
Not yet available |
|
|
|
